Cargando…
Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
OBJECTIVES: Both prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment. SETTING: This study uses observational data f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857670/ https://www.ncbi.nlm.nih.gov/pubmed/29549214 http://dx.doi.org/10.1136/bmjopen-2017-020787 |
_version_ | 1783307511300882432 |
---|---|
author | Crawley, Danielle Garmo, Hans Rudman, Sarah Stattin, Pär Zethelius, Björn Armes, Jo Holmberg, Lars Adolfsson, Jan Van Hemelrijck, Mieke |
author_facet | Crawley, Danielle Garmo, Hans Rudman, Sarah Stattin, Pär Zethelius, Björn Armes, Jo Holmberg, Lars Adolfsson, Jan Van Hemelrijck, Mieke |
author_sort | Crawley, Danielle |
collection | PubMed |
description | OBJECTIVES: Both prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment. SETTING: This study uses observational data from Prostate Cancer database Sweden Traject. PARTICIPANTS: The study was undertaken in a cohort of 16 778 men with T2DM, of whom 962 were diagnosed with PCa during mean follow-up of 2.5 years. PRIMARY AND SECONDARY OUTCOME MEASURES: We investigated the association between PCa diagnosis and escalation in T2DM treatment in this cohort. A treatment escalation was defined as a new or change in anti-T2DM prescription, as recorded in the prescribed drug register (ie, change from diet to metformin or sulphonylurea or insulin). We also investigated how PCa diagnosis was associated with two treatment escalations. Multivariate Cox proportional hazards regression with age as a time scale was used while adjusting for educational level and initial T2DM treatment. RESULTS: We found no association between PCa diagnosis and risk of a single treatment escalation (HR 0.99, 95% CI 0.87 to 1.13). However, PCa diagnosis was associated with an increased risk of receiving two consecutive T2DM treatment escalations (HR 1.75, 95% CI 1.38 to 2.22). This increase was strongest for men on gonadotropin-releasing hormone (GnRH) agonists (HR 3.08, 95% CI 2.14 to 4.40). The corresponding HR for men with PCa not on hormonal treatment was 1.40 (95% CI 1.03 to 1.92) and for men with PCa on antiandrogens 0.91 (95% CI 0.29 to 2.82). CONCLUSIONS: Men with T2DM who are diagnosed with PCa, particularly those treated with GnRH agonists, were more likely to have two consecutive escalations in T2DM treatment. This suggests a need for closer monitoring of men with both PCa and T2DM, as coexistence of PCa and its subsequent treatments could potentially worsen T2DM control. |
format | Online Article Text |
id | pubmed-5857670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58576702018-03-20 Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study Crawley, Danielle Garmo, Hans Rudman, Sarah Stattin, Pär Zethelius, Björn Armes, Jo Holmberg, Lars Adolfsson, Jan Van Hemelrijck, Mieke BMJ Open Oncology OBJECTIVES: Both prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment. SETTING: This study uses observational data from Prostate Cancer database Sweden Traject. PARTICIPANTS: The study was undertaken in a cohort of 16 778 men with T2DM, of whom 962 were diagnosed with PCa during mean follow-up of 2.5 years. PRIMARY AND SECONDARY OUTCOME MEASURES: We investigated the association between PCa diagnosis and escalation in T2DM treatment in this cohort. A treatment escalation was defined as a new or change in anti-T2DM prescription, as recorded in the prescribed drug register (ie, change from diet to metformin or sulphonylurea or insulin). We also investigated how PCa diagnosis was associated with two treatment escalations. Multivariate Cox proportional hazards regression with age as a time scale was used while adjusting for educational level and initial T2DM treatment. RESULTS: We found no association between PCa diagnosis and risk of a single treatment escalation (HR 0.99, 95% CI 0.87 to 1.13). However, PCa diagnosis was associated with an increased risk of receiving two consecutive T2DM treatment escalations (HR 1.75, 95% CI 1.38 to 2.22). This increase was strongest for men on gonadotropin-releasing hormone (GnRH) agonists (HR 3.08, 95% CI 2.14 to 4.40). The corresponding HR for men with PCa not on hormonal treatment was 1.40 (95% CI 1.03 to 1.92) and for men with PCa on antiandrogens 0.91 (95% CI 0.29 to 2.82). CONCLUSIONS: Men with T2DM who are diagnosed with PCa, particularly those treated with GnRH agonists, were more likely to have two consecutive escalations in T2DM treatment. This suggests a need for closer monitoring of men with both PCa and T2DM, as coexistence of PCa and its subsequent treatments could potentially worsen T2DM control. BMJ Publishing Group 2018-03-16 /pmc/articles/PMC5857670/ /pubmed/29549214 http://dx.doi.org/10.1136/bmjopen-2017-020787 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Oncology Crawley, Danielle Garmo, Hans Rudman, Sarah Stattin, Pär Zethelius, Björn Armes, Jo Holmberg, Lars Adolfsson, Jan Van Hemelrijck, Mieke Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study |
title | Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study |
title_full | Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study |
title_fullStr | Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study |
title_full_unstemmed | Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study |
title_short | Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study |
title_sort | does a prostate cancer diagnosis affect management of pre-existing diabetes? results from pcbase sweden: a nationwide cohort study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857670/ https://www.ncbi.nlm.nih.gov/pubmed/29549214 http://dx.doi.org/10.1136/bmjopen-2017-020787 |
work_keys_str_mv | AT crawleydanielle doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT garmohans doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT rudmansarah doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT stattinpar doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT zetheliusbjorn doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT armesjo doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT holmberglars doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT adolfssonjan doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy AT vanhemelrijckmieke doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy |